Ophthalmology
Volume 114, Issue 6 , Pages 1039-1045 , June 2007

Association between Genetic Polymorphisms of the Prostaglandin F2α Receptor Gene and Response to Latanoprost

Presented at: Joint Meeting of the American Academy of Ophthalmology and Asia Pacific Academy of Ophthalmology, November 2006, Las Vegas, Nevada.

  • Mayumi Sakurai, MSc
    • ,
  • Tomomi Higashide, MD, PhD

      Affiliations

    • Corresponding Author InformationCorrespondence and reprint requests to Tomomi Higashide, MD, PhD, Department of Ophthalmology and Visual Science, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
    • ,
  • Mami Takahashi, MD
    • ,
  • Kazuhisa Sugiyama, MD, PhD

Received 4 August 2006 ,Accepted 12 March 2007.

References 

  1. Aung T, Chew PT, Yip CC, et al. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2001;131:636–642
  2. Scherer WJ. A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther. 2002;18:287–291
  3. Sofowora GG, Dishy V, Muszkat M, et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther. 2003;73:366–371
  4. Brodde OE, Stein CM. The Gly389Arg beta1-adrenergic receptor polymorphism: a predictor of response to beta-blocker treatment?. Clin Pharmacol Ther. 2003;74:299–302
  5. Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 1997;100:3184–3188
  6. Evans WE, McLeod HL. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538–549
  7. Sasaki M, Oki T, Iuchi A, et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens. 1996;14:1403–1408
  8. Baudin B. Angiotensin II receptor polymorphisms in hypertension: pharmacogenomic considerations. Pharmacogenomics. 2002;3:65–73
  9. Miller JA, Thai K, Scholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int. 1999;56:2173–2180
  10. Schwartz SG, Puckett BJ, Allen RC, et al. β1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers. Ophthalmology. 2005;112:2131–2136
  11. Stjernschantz J, Selen G, Sjoquist B, Resul B. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:513–518
  12. Abramovitz M, Boie Y, Nguyen T, et al. Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem. 1994;269:2632–2636
  13. Betz R, Lagercrantz J, Kedra D, et al. Genomic structure, 5′ flanking sequences, and precise localization in 1P31.1 of the human prostaglandin F receptor gene. Biochem Biophys Res Commun. 1999;254:413–416
  14. Vielhauer GA, Fujino H, Regan JW. Cloning and localization of hFP(S): a six-transmembrane mRNA splice variant of the human FP prostanoid receptor. Arch Biochem Biophys. 2004;421:175–185
  15. Ocklind A, Lake S, Wentzel P, et al. Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci. 1996;37:716–726
  16. Schlotzer-Schrehardt U, Zenkel M, Nusing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43:1475–1487
  17. Mukhopadhyay P, Bian L, Yin H, et al. Localization of EP(1) and FP receptors in human ocular tissues by in situ hybridization. Invest Ophthalmol Vis Sci. 2001;42:424–428
  18. Watanabe T, Nakao A, Emerling D, et al. Prostaglandin F2 alpha enhances tyrosine phosphorylation and DNA synthesis through phospholipase C-coupled receptor via Ca(2+)-dependent intracellular pathway in NIH-3T3 cells. J Biol Chem. 1994;269:17619–17625
  19. Sugimoto Y, Hasumoto K, Namba T, et al. Cloning and expression of a cDNA for mouse prostaglandin F receptor. J Biol Chem. 1994;269:1356–1360
  20. Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38:2772–2780
  21. Gaton DD, Sagara T, Lindsey JD, et al. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol. 2001;119:1165–1170
  22. Weinreb RN, Lindsey JD. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci. 2002;43:716–722
  23. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 1997;38:2214–2223
  24. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle: a study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179–191
  25. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297–1304
  26. Crowston JG, Lindsey JD, Aihara M, Weinreb RN. Effect of latanoprost on intraocular pressure in mice lacking prostaglandin FP receptor. Invest Ophthalmol Vis Sci. 2004;45:3555–3559
  27. Zaragoza DB, Wilson R, Eyster K, Olson DM. Cloning and characterization of the promoter region of the human prostaglandin F2alpha receptor gene. Biochim Biophys Acta. 2004;1676:193–202
  28. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol. 1995;12:921–927
  29. Stjernschantz JW. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan (The Proctor Lecture). Invest Ophthalmol Vis Sci. 2001;42:1134–1145
  30. Rulo AH, Greve EL, Geijssen HC, Hoyng PF. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology. 1996;103:1276–1282
  31. Tamada Y, Taniguchi T, Murase H, et al. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. J Ocul Pharmacol Ther. 2001;17:19–25
  32. Ezashi T, Sakamoto K, Miwa K, et al. Genomic organization and characterization of the gene encoding bovine prostaglandin F2alpha receptor. Gene. 1997;190:271–278
  33. Neuschafer-Rube F, Moller U, Puschel GP. Structure of the 5′-flanking region of the rat prostaglandin F(2alpha) receptor gene and its transcriptional control functions in hepatocytes. Biochem Biophys Res Commun. 2000;278:278–285
  34. Neuschafer-Rube F, Engemaier E, Koch S, et al. Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J. 2003;371:443–449
  35. Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 2002;47(suppl):S34–S40
  36. Orlicky DJ. Negative regulatory activity of a prostaglandin F2 alpha receptor associated protein (FPRP). Prostaglandins Leukot Essent Fatty Acids. 1996;54:247–259
  37. Van Der Zwaag B, Verzijl HT, Beltran-Valero de Bernabe D, et al. Mutation analysis in the candidate Mobius syndrome genes PGT and GATA2 on chromosome 3 and EGR2 on chromosome 10. [letter online] J Med Genet. 2002;39:E30;Available at http://jmg.bmjjournals.com/cgi/content/full/39/6/e30. Accessed June 30, 2002
  38. Sipe JC, Chiang K, Gerber AL, et al. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci U S A. 2002;99:8394–8399
  39. Rutter JL, Mitchell TI, Buttice G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998;58:5321–5325
  40. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem. 2001;276:7549–7558
  41. Ye S, Watts GF, Mandalia S, et al. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J. 1995;73:209–215
  42. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999;99:1788–1794
  43. St Jean PL, Zhang XC, Hart BK, et al. Characterization of a dinucleotide repeat in the 92 kDa type IV collagenase gene (CLG4B), localization of CLG4B to chromosome 20 and the role of CLG4B in aortic aneurysmal disease. Ann Hum Genet. 1995;59:17–24

 Manuscript no. 2006-874.

 Financial support: Japan Society for the Promotion of Science, Tokyo, Japan (Grant-in-Aid for Scientific Research no. 17591826).

PII: S0161-6420(07)00306-5

doi: 10.1016/j.ophtha.2007.03.025

Ophthalmology
Volume 114, Issue 6 , Pages 1039-1045 , June 2007

Article Tools

* Image Usage & Resolution